Skip to main content
Premium Trial:

Request an Annual Quote

Agilent s LSCA Unit Posts Double-Digit Growth in Orders, Revenues for Q1 2005

NEW YORK, Feb. 14 (GenomeWeb News) - Agilent Technologies' Life Science and Chemical Analysis business unit today reported a 16-percent increase in orders for the quarter ended Jan. 31, 2005, accompanied by a 13-percent rise in revenues and a 9-percent increase in profits.


Agilent's LSCA group, which houses the company's genomics and proteomics product lines, reported orders of $356 million for the first quarter of its 2005 fiscal year, up sharply from $307 million in orders for the year-ago quarter.


Life Science orders increased 18 percent, while Chemical Analysis orders increased by 15 percent, the company said.


The LSCA unit posted first-quarter revenues of $354 million, compared to $313 million in the first quarter of fiscal 2004.


Segment profits rose to $51 million, from $47 million in the prior-year period. 


The LSCA unit's revenues made up 21 percent of Agilent's $1.66 billion in total revenues for the quarter, which rose only 1 percent over last year's first-quarter revenues.


Total orders for the company - including LSCA, Test and Measurement, Automated Test, and Semiconductor Products - dropped 7 percent year-over-year to $1.61 billion.


First-quarter net earnings were $103 million, or $.21 per diluted share, compared to $71 million, or $.14 per share, in the first quarter of 2004.


Agilent spent a total of $232 million on R&D during the quarter, up slightly from $229 million last year.


The company had $2.5 billion in cash and cash equivalents on hand as of Jan. 31.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more